In last trading session, Oncology Institute Inc (NASDAQ:TOI) saw 0.51 million shares changing hands with its beta currently measuring 0.85. Company’s recent per share price level of $2.31 trading at $0.25 or 11.89% at ring of the bell on the day assigns it a market valuation of $169.99M. That closing price of TOI’s stock is at a discount of -14.72% from its 52-week high price of $2.65 and is indicating a premium of 85.71% from its 52-week low price of $0.33. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.47 million shares which gives us an average trading volume of 220.09K if we extend that period to 3-months.
For Oncology Institute Inc (TOI), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.11 in the current quarter.
Oncology Institute Inc (NASDAQ:TOI) trade information
Upright in the green during last session for gaining 11.89%, in the last five days TOI remained trading in the red while hitting it’s week-highest on Monday, 11/13/23 when the stock touched $2.31 price level, adding 12.83% to its value on the day. Oncology Institute Inc’s shares saw a change of 39.70% in year-to-date performance and have moved -6.68% in past 5-day. Oncology Institute Inc (NASDAQ:TOI) showed a performance of 48.71% in past 30-days. Number of shares sold short was 0.23 million shares which calculate 1.76 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $2.50 to the stock, which implies a rise of 7.6% to its current value. Analysts have been projecting $2.50 as a low price target for the stock while placing it at a high target of $2.50. It follows that stock’s current price would drop -8.23% in reaching the projected high whereas dropping to the targeted low would mean a loss of -8.23% for stock’s current value.
Oncology Institute Inc (TOI) estimates and forecasts
Statistics highlight that Oncology Institute Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 436.05% of value to its shares in past 6 months, showing an annual growth rate of -27.50% while that of industry is 5.60. Apart from that, the company came lowering its revenue forecast for fiscal year 2023. This year revenue growth is estimated to rise 26.90% from the last financial year’s standing.
1 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $82.04 million for the same. And 1 analysts are in estimates of company making revenue of $85 million in the next quarter that will end on Mar 2024. Company posted $71.42 million and $76.19 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 14.90% while estimating it to be 11.60% for the next quarter.
Oncology Institute Inc is more likely to be releasing its next quarterly report on November 08 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.